A small n sequential multiple assignment randomized trial design for use in rare disease research

Contemporary Clinical Trials

Volumn 46, Issue , 2016, Pages 48-51

  Tamura, Roy N ^a   Krischer, Jeffrey P ^a   Pagnoux, Christian ^b   Micheletti, Robert ^c   Grayson, Peter C ^d   Chen, Yeh Fong ^e   Merkel, Peter A ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Binary data; Re randomization; Weighted Z statistic

Indexed keywords

ARTICLE; CLINICAL RESEARCH; COMPUTER SIMULATION; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RARE DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PROCEDURES; SAMPLE SIZE; STATISTICS;

CLINICAL TRIALS, PHASE II AS TOPIC; COMPUTER SIMULATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RARE DISEASES; SAMPLE SIZE; STATISTICS AS TOPIC;

EID: 84947719802     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2015.11.010     Document Type: Article

References (14)

1. Griggs R.C., Batshaw M., Dunkle M., Gopal-Srivastava R., Kaye E., Krischer J., Nguyen T., Paulus K., Merkel P.A. Clinical research for rare disease: opportunities, challenges, and solutions. Mol. Genet. Metab. 2009, 96:20-26.
2. iRDirC-EMA Preparatory document for joint workshop on small population clinical trials challenges in the field of rare disease August 19 2015, European Medicines Agency.
3. Murphy S.A. An experimental design for the development of adaptive treatment strategies. Stat. Med. 2005, 24:1455-1481.
4. Lavori P.W., Dawson R. Introduction to dynamic treatment strategies and sequential multiple assignment randomization. Clin. Trials 2014, 11:393-399.
5. Thall P.F., Millikan R.E., Sug H.G. Evaluating multiple treatment courses in clinical trials. Stat. Med. 2000, 19:1011-1028.
6. Jones H. 2010, MD: National Institute of Health, Bethesda, (http://clinicaltrials.gov/ct2/show/NCT01177982).
7. Oslin D. Managing alcoholism in people who do not respond to naltrexone (EXTEND) 2005, MD: National Institute of Health, Bethesda, (http://clinicaltrials.gov/ct2/show/NCT001150337).
8. Simon R., Wittes R.E., Ellenberg S.S. Randomized phase II trials. Cancer Treat. Rep. 1985, 12:1375-1381.
9. Fava M., Evins A.E., Dorer D.J., Schoenfeld D.A. The problem of the placebo response in clinical trials for psychiatric disorders; culprits, possible remedies, and a novel study design approach. Psychother. Psychosom. 2003, 72:115-127.
10. Thall P.F., Simon R., Ellenberg S.S. Two-stage selection and testing for comparative clinical trials. Biometrika 1988, 75:303-310.
11. Kim W.C. On detecting the best treatment. J. Korean Stat. Soc. 1988, 17:82-92.
12. Mehotra D.V., Railkar R. Minimum risk weights for comparing treatments in stratified binomial trials. Stat. Med. 2000, 19:811-825.
13. Nahum-Shani I., Almirall D., Fabiano G.A., Yu J., Qian M., Pelham W., Gnagy B., Waxmonsky J.G., Murphy S.A. Experimental design and primary data analysis methods for comparing adaptive interventions. Psychol. Methods 2012, 457-477.
14. Signorovitch J.E., Wu E.Q., Yu A.P., Gerrits C.M., Kantor E., Bao Y., Gupta S.R., Mulani P.M. Comparative effectiveness without head-to-head trials. PharmacoEconomics 2010, 28:935-945.